Autoimmune atherosclerosis in 3D: How it develops, how to diagnose and what to do

Autoimmunity Reviews

Volumn 15, Issue 7, 2016, Pages 756-769

  Szekanecz, Zoltán ^a   Kerekes, György ^a   Végh, Edit ^a   Kardos, Zsófia ^b   Baráth, Zsuzsa ^b   Tamási, László ^b   Shoenfeld, Yehuda ^c  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b Semmelweis Teaching Hospital   (Hungary)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

Arthritis; Atherosclerosis; Autoimmunity; Biologics; Cardiovascular disease; Risk assessment

Indexed keywords

ACETYLSALICYLIC ACID; AUTOANTIBODY; BIOLOGICAL MARKER; CHEMOKINE; CORTICOSTEROID; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEINASE;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CARDIOVASCULAR RISK; HIGH RISK PATIENT; HUMAN; INFLAMMATION; INFLAMMATORY CELL; NON INVASIVE PROCEDURE; PATHOPHYSIOLOGY; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; TREATMENT OUTCOME; CARDIOVASCULAR DISEASES; COMPLICATION; DIAGNOSTIC IMAGING; MORTALITY; RISK FACTOR;

ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; AUTOIMMUNE DISEASES; CARDIOVASCULAR DISEASES; HUMANS; RISK FACTORS;

EID: 84962137597     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2016.03.014     Document Type: Review

References (218)

1. Shoenfeld Y., Gerli R., Doria A., Matsuura E., Cerinic M.M., Ronda N., et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005, 112(21):3337-3347.
2. Szekanecz Z., Kerekes G., Der H., Sandor Z., Szabo Z., Vegvari A., et al. Accelerated atherosclerosis in rheumatoid arthritis. Ann N Y Acad Sci 2007, 1108:349-358.
3. Szekanecz Z., Kerekes G., Kardos Z., Baráth Z., Tamási L. Mechanisms of inflammatory atherosclerosis in rheumatoid arthritis. Curr Immunol Rev 2016, [in press].
4. Symmons D.P., Gabriel S.E. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol 2011, 7(7):399-408.
5. Nurmohamed M.T., Heslinga M., Kitas G.D. Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol 2015, 11(12):693-704.
6. Wu G.C., Liu H.R., Leng R.X., Li X.P., Li X.M., Pan H.F., et al. Subclinical atherosclerosis in patients with systemic lupus erythematosus: a systemic review and meta-analysis. Autoimmun Rev 2016, 15(1):22-37.
7. Frieri M. Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches. Curr Allergy Asthma Rep 2012, 12(1):25-32.
8. Denas G., Jose S.P., Bracco A., Zoppellaro G., Pengo V. Antiphospholipid syndrome and the heart: a case series and literature review. Autoimmun Rev 2015, 14(3):214-222.
9. Szucs G., Timar O., Szekanecz Z., Der H., Kerekes G., Szamosi S., et al. Endothelial dysfunction precedes atherosclerosis in systemic sclerosis-relevance for prevention of vascular complications. Rheumatology (Oxford) 2007, 46(5):759-762.
10. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340(2):115-126.
11. Sherer Y., Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2006, 2(2):99-106.
12. Hansson G.K., Jonasson L., Seifert P.S., Stemme S. Immune mechanisms in atherosclerosis. Arteriosclerosis 1989, 9(5):567-578.
13. Skeoch S., Bruce I.N. Atherosclerosis in rheumatoid arthritis: is it all about inflammation?. Nat Rev Rheumatol 2015, 11(7):390-400.
14. Dougados M., Soubrier M., Antunez A., Balint P., Balsa A., Buch M.H., et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 2014, 73(1):62-68.
15. Houri Levi E., Watad A., Whitby A., Tiosano S., Comaneshter D., Cohen A.D., et al. Coexistence of ischemic heart disease and rheumatoid arthritis patients-a case control study. Autoimmun Rev 2016, 15(4):393-396.
16. Crepaldi G., Scire C.A., Carrara G., Sakellariou G., Caporali R., Hmamouchi I., et al. Cardiovascular comorbidities relate more than others with disease activity in rheumatoid arthritis. PLoS One 2016, 11(1).
17. Innala L., Sjoberg C., Moller B., Ljung L., Smedby T., Sodergren A., et al. Co-morbidity in patients with early rheumatoid arthritis - inflammation matters. Arthritis Res Ther 2016, 18(1):33.
18. Mantel A., Holmqvist M., Nyberg F., Tornling G., Frisell T., Alfredsson L., et al. Risk factors for the rapid increase in risk of acute coronary events in patients with new-onset rheumatoid arthritis: a nested case-control study. Arthritis Rheumatol 2015, 67(11):2845-2854.
19. Arts E.E., Fransen J., den Broeder A.A., Popa C.D., van Riel P.L. The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients. Ann Rheum Dis 2015, 74(6):998-1003.
20. Solomon D.H., Reed G.W., Kremer J.M., Curtis J.R., Farkouh M.E., Harrold L.R., et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol 2015, 67(6):1449-1455.
21. Myasoedova E., Chandran A., Ilhan B., Major B.T., Michet C.J., Matteson E.L., et al. The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease. Ann Rheum Dis 2016, 75(3):560-565.
22. Gonzalez A., Maradit Kremers H., Crowson C.S., Nicola P.J., Davis J.M., Therneau T.M., et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007, 56(11):3583-3587.
23. Peters M.J., van Halm V.P., Voskuyl A.E., Smulders Y.M., Boers M., Lems W.F., et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 2009, 61(11):1571-1579.
24. Van Doornum S., Bohensky M., Tacey M.A., Brand C.A., Sundararajan V., Wicks I.P. Increased 30-day and 1-year mortality rates and lower coronary revascularisation rates following acute myocardial infarction in patients with autoimmune rheumatic disease. Arthritis Res Ther 2015, 17:38.
25. Humphreys J.H., Warner A., Chipping J., Marshall T., Lunt M., Symmons D.P., et al. Mortality trends in patients with early rheumatoid arthritis over 20 years: results from the Norfolk arthritis register. Arthritis Care Res (Hoboken) 2014, 66(9):1296-1301.
26. Meek I.L., Vonkeman H.E., van de Laar M.A. Cardiovascular case fatality in rheumatoid arthritis is decreasing; first prospective analysis of a current low disease activity rheumatoid arthritis cohort and review of the literature. BMC Musculoskelet Disord 2014, 15:142.
27. Nurmohamed M. EULAR recommendation update on cardiovascular disease in RA. Ann Rheum Dis 2015, 74(Suppl. 2):9.
28. Peters M.J., Symmons D.P., McCarey D., Dijkmans B.A., Nicola P., Kvien T.K., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010, 69(2):325-331.
29. Van Doornum S., McColl G., Wicks I.P. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?. Arthritis Rheum 2002, 46(4):862-873.
30. Chuang Y.W., Yu M.C., Lin C.L., Yu T.M., Shu K.H., Huang S.T., et al. Risk of peripheral arterial occlusive disease in patients with rheumatoid arthritis. A nationwide population-based cohort study. Thromb Haemost 2016, 115(2):439-445.
31. Baghdadi L.R., Woodman R.J., Shanahan E.M., Mangoni A.A. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS One 2015, 10(2).
32. Klareskog L., Padyukov L., Lorentzen J., Alfredsson L. Mechanisms of disease: genetic susceptibility and environmental triggers in the development of rheumatoid arthritis. Nat Clin Pract Rheumatol 2006, 2(8):425-433.
33. Padyukov L., Silva C., Stolt P., Alfredsson L., Klareskog L. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum 2004, 50(10):3085-3092.
34. Szodoray P., Szabo Z., Kapitany A., Gyetvai A., Lakos G., Szanto S., et al. Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. Autoimmun Rev 2010, 9:140-143.
35. Zhang J., Fu L., Shi J., Chen X., Li Y., Ma B., et al. The risk of metabolic syndrome in patients with rheumatoid arthritis: a meta-analysis of observational studies. PLoS One 2013, 8(10).
36. da Cunha V.R., Brenol C.V., Brenol J.C., Fuchs S.C., Arlindo E.M., Melo I.M., et al. Metabolic syndrome prevalence is increased in rheumatoid arthritis patients and is associated with disease activity. Scand J Rheumatol 2012, 41(3):186-191.
37. Kerekes G., Nurmohamed M.T., Gonzalez-Gay M.A., Seres I., Paragh G., Kardos Z., et al. Rheumatoid arthritis and metabolic syndrome. Nat Rev Rheumatol 2014, 10:691-696.
38. Summers G.D., Metsios G.S., Stavropoulos-Kalinoglou A., Kitas G.D. Rheumatoid cachexia and cardiovascular disease. Nat Rev Rheumatol 2010, 6(8):445-451.
39. Roubenoff R. Rheumatoid cachexia: a complication of rheumatoid arthritis moves into the 21st century. Arthritis Res Ther 2009, 11(2):108.
40. Smolen J.S., Landewe R., Breedveld F.C., Dougados M., Emery P., Gaujoux-Viala C., Gorter S., Knevel R., Nam J., Schoels M., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2013, 69(6):964-975.
41. Escalante A., Haas R.W., del Rincon I. Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 2005, 165(14):1624-1629.
42. Arikawa T., Watanabe K., Seki M., Matsukawa A., Oomizu S., Sakata K.M., et al. Galectin-9 ameliorates immune complex-induced arthritis by regulating Fc gamma R expression on macrophages. Clin Immunol 2009, 133(3):382-392.
43. Rall L.C., Roubenoff R. Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology (Oxford) 2004, 43(10):1219-1223.
44. Wesley A., Bengtsson C., Elkan A.C., Klareskog L., Alfredsson L., Wedren S. Association between body mass index and anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis: results from a population-based case-control study. Arthritis Care Res (Hoboken) 2013, 65:107-112.
45. Myasoedova E., Crowson C.S., Kremers H.M., Roger V.L., Fitz-Gibbon P.D., Therneau T.M., et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011, 70(3):482-487.
46. Johnsson H., Panarelli M., Cameron A., Sattar N. Analysis and modelling of cholesterol and high-density lipoprotein cholesterol changes across the range of C-reactive protein levels in clinical practice as an aid to better understanding of inflammation-lipid interactions. Ann Rheum Dis 2014, 73(8):1495-1499.
47. Pedersen M., Jacobsen S., Klarlund M., Pedersen B.V., Wiik A., Wohlfahrt J., et al. Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis Res Ther 2006, 8(4):R133.
48. Giles J.T., Allison M., Blumenthal R.S., Post W., Gelber A.C., Petri M., et al. Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics. Arthritis Rheum 2010, 62(11):3173-3182.
49. Ferraz-Amaro I., Gonzalez-Juanatey C., Lopez-Mejias R., Riancho-Zarrabeitia L., Gonzalez-Gay M.A. Metabolic syndrome in rheumatoid arthritis. Mediators Inflamm 2013, 2013:710928.
50. Myasoedova E., Crowson C.S., Kremers H.M., Fitz-Gibbon P.D., Therneau T.M., Gabriel S.E. Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis 2010, 69(7):1310-1314.
51. Hurt-Camejo E., Paredes S., Masana L., Camejo G., Sartipy P., Rosengren B., et al. Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile. Arthritis Rheum 2001, 44(12):2761-2767.
52. Rizzo M., Spinas G.A., Cesur M., Ozbalkan Z., Rini G.B., Berneis K. Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naive patients with early rheumatoid arthritis. Atherosclerosis 2009, 207(2):502-506.
53. Hahn B.H., Grossman J., Chen W., McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 2007, 28(2-3):69-75.
54. Montecucco F., Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford) 2009, 48(1):11-22.
55. Wang J., Hu B., Kong L., Cai H., Zhang C. Native, oxidized lipoprotein(a) and lipoprotein(a) immune complex in patients with active and inactive rheumatoid arthritis: plasma concentrations and relationship to inflammation. Clin Chim Acta 2008, 390(1-2):67-71.
56. Ronda N., Favari E., Borghi M.O., Ingegnoli F., Gerosa M., Chighizola C., et al. Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 2013.
57. Eren E., Yilmaz N., Aydin O. High density lipoprotein and it's dysfunction. Open Biochem J 2012, 6:78-93.
58. Tanimoto N., Kumon Y., Suehiro T., Ohkubo S., Ikeda Y., Nishiya K., et al. Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sci 2003, 72(25):2877-2885.
59. Asanuma Y., Kawai S., Aoshima H., Kaburaki J., Mizushima Y. Serum lipoprotein(a) and apolipoprotein(a) phenotypes in patients with rheumatoid arthritis. Arthritis Rheum 1999, 42(3):443-447.
60. Dursunoglu D., Evrengul H., Polat B., Tanriverdi H., Cobankara V., Kaftan A., et al. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol Int 2005, 25(4):241-245.
61. Meek I.L., Vonkeman H.E., van de Laar M.A. Hyperuricaemia: a marker of increased cardiovascular risk in rheumatic patients: analysis of the ACT-CVD cohort. BMC Musculoskelet Disord 2014, 15:174.
62. Farragher T.M., Goodson N.J., Naseem H., Silman A.J., Thomson W., Symmons D., et al. Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum 2008, 58(2):359-369.
63. Rodriguez-Rodriguez L., Lopez-Mejias R., Fernandez-Gutierrez B., Balsa A., Gonzalez-Gay M.A., Martin J. Rheumatoid arthritis: genetic variants as biomarkers of cardiovascular disease. Curr Pharm Des 2015, 21(2):182-201.
64. Davis L.A., Whitfield E., Cannon G.W., Wolff R.K., Johnson D.S., Reimold A.M., et al. Association of rheumatoid arthritis susceptibility gene with lipid profiles in patients with rheumatoid arthritis. Rheumatology (Oxford) 2014, 53(6):1014-1021.
65. Ibrahim I., Humphreys J., Mokhtar I., Marshall T., Verstappen S., Symmons D., et al. Association of chemokine CXC ligand 12 gene polymorphism (rs1746048) with cardiovascular mortality in patients with rheumatoid arthritis: results from the Norfolk arthritis register. Ann Rheum Dis 2015, 74(11):2099-2102.
66. Chassaing B., Gewirtz A.T. Gut microbiota, low-grade inflammation, and metabolic syndrome. Toxicol Pathol 2014, 42(1):49-53.
67. Curran S.A., Hollan I., Erridge C., Lappin D.F., Murray C.A., Sturfelt G., et al. Bacteria in the adventitia of cardiovascular disease patients with and without rheumatoid arthritis. PLoS One 2014, 9(5).
68. Szekanecz Z., Koch A.E. Vascular endothelium and immune responses: implications for inflammation and angiogenesis. Rheum Dis Clin North Am 2004, 30(1):97-114.
69. Szekanecz Z., Koch A.E. Endothelial cells in inflammation and angiogenesis. Curr Drug Targets Inflamm Allergy 2005, 4(3):319-323.
70. Kobezda T., Ghassemi-Nejad S., Mikecz K., Glant T.T., Szekanecz Z. Of mice and men: how animal models advance our understanding of T-cell function in RA. Nat Rev Rheumatol 2014, 10(3):160-170.
71. Zhu M., Mo H., Li D., Luo X., Zhang L. Th17/Treg imbalance induced by increased incidence of atherosclerosis in patients with systemic lupus erythematosus (SLE). Clin Rheumatol 2013, 32(7):1045-1052.
72. Chistiakov D.A., Sobenin I.A., Orekhov A.N. Regulatory T cells in atherosclerosis and strategies to induce the endogenous atheroprotective immune response. Immunol Lett 2013, 151(1-2):10-22.
73. Gerli R., Schillaci G., Giordano A., Bocci E.B., Bistoni O., Vaudo G., et al. CD4 + CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 2004, 109(22):2744-2748.
74. Szekanecz Z., Szegedi G., Koch A.E. Cellular adhesion molecules in rheumatoid arthritis: regulation by cytokines and possible clinical importance. J Invest Med 1996, 44(4):124-135.
75. Gonzalez-Gay M.A., Garcia-Unzueta M.T., De Matias J.M., Gonzalez-Juanatey C., Garcia-Porrua C., Sanchez-Andrade A., et al. Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006, 24(4):373-379.
76. Ridker P.M., Hennekens C.H., Roitman-Johnson B., Stampfer M.J., Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998, 351(9096):88-92.
77. Toubi E., Shoenfeld Y. The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity 2004, 37(6-7):457-464.
78. Lobbes M.B., Lutgens E., Heeneman S., Cleutjens K.B., Kooi M.E., van Engelshoven J.M., et al. Is there more than C-reactive protein and fibrinogen? The prognostic value of soluble CD40 ligand, interleukin-6 and oxidized low-density lipoprotein with respect to coronary and cerebral vascular disease. Atherosclerosis 2006, 187(1):18-25.
79. Risbud M.V., Shapiro I.M. Role of cytokines in intervertebral disc degeneration: pain and disc content. Nat Rev Rheumatol 2013, 10(1):44-56.
80. Ridker P.M., Rifai N., Pfeffer M., Sacks F., Lepage S., Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000, 101(18):2149-2153.
81. Szekanecz Z. Pro-inflammatory cytokines in atherosclerosis. Isr Med Assoc J 2008, 10(7):529-530.
82. Popa C., Netea M.G., van Riel P.L., van der Meer J.W., Stalenhoef A.F. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res 2007, 48(4):751-762.
83. Ahmed A., Hollan I., Curran S.A., Kitson S.M., Riggio M.P., Mikkelsen K., et al. Rheumatoid arthritis patients have a pro-atherogenic cytokine microenvironment in the aortic adventitia. Arthritis Rheumatol 2016.
84. Coca A., Sanz I. B cell depletion in lupus and Sjogren's syndrome: an update. Curr Opin Rheumatol 2009, 21(5):483-488.
85. Ridker P.M. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. Am Heart J 2004, 148(1 Suppl.):S19-S26.
86. Kerekes G., Szekanecz Z., Der H., Sandor Z., Lakos G., Muszbek L., et al. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J Rheumatol 2008, 35(3):398-406.
87. Gotsman I., Stabholz A., Planer D., Pugatsch T., Lapidus L., Novikov Y., et al. Serum cytokine tumor necrosis factor-alpha and interleukin-6 associated with the severity of coronary artery disease: indicators of an active inflammatory burden?. Isr Med Assoc J 2008, 10(7):494-498.
88. Szekanecz Z., Koch A.E., Kunkel S.L., Strieter R.M. Cytokines in rheumatoid arthritis. Potential targets for pharmacological intervention. Drugs Aging 1998, 12(5):377-390.
89. Blankenberg S., Tiret L., Bickel C., Peetz D., Cambien F., Meyer J., et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002, 106(1):24-30.
90. Szekanecz Z., Vegvari A., Szabo Z., Koch A.E. Chemokines and chemokine receptors in arthritis. Front Biosci (Schol Ed) 2010, 2:153-167.
91. Martinovic I., Abegunewardene N., Seul M., Vosseler M., Horstick G., Buerke M., et al. Elevated monocyte chemoattractant protein-1 serum levels in patients at risk for coronary artery disease. Circ J 2005, 69(12):1484-1489.
92. White G.E., Greaves D.R. Fractalkine: one chemokine, many functions. Blood 2009, 113(4):767-768.
93. Nishimura M., Umehara H., Nakayama T., Yoneda O., Hieshima K., Kakizaki M., et al. Dual functions of fractalkine/CX3C ligand 1 in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J Immunol 2002, 168(12):6173-6180.
94. Le N.T., Xue M., Castelnoble L.A., Jackson C.J. The dual personalities of matrix metalloproteinases in inflammation. Front Biosci 2007, 12:1475-1487.
95. Takaishi H., Kimura T., Dalal S., Okada Y., D'Armiento J. Joint diseases and matrix metalloproteinases: a role for MMP-13. Curr Pharm Biotechnol 2008, 9(1):47-54.
96. Chen F., Eriksson P., Hansson G.K., Herzfeld I., Klein M., Hansson L.O., et al. Expression of matrix metalloproteinase 9 and its regulators in the unstable coronary atherosclerotic plaque. Int J Mol Med 2005, 15(1):57-65.
97. Deguchi J.O., Aikawa M., Tung C.H., Aikawa E., Kim D.E., Ntziachristos V., et al. Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation 2006, 114(1):55-62.
98. Gomez R., Conde J., Scotece M., Gomez-Reino J.J., Lago F., Gualillo O. What's new in our understanding of the role of adipokines in rheumatic diseases?. Nat Rev Rheumatol 2011, 7(9):528-536.
99. Hadji P., Gnant M., Body J.J., Bundred N.J., Brufsky A., Coleman R.E., Guise T.A., Lipton A., Aapro M.S. Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention?. Cancer Treat Rev 2012, 38(6):798-806.
100. Lee S.E., Kim H.S. Human resistin in cardiovascular disease. J Smooth Muscle Res 2012, 48(1):27-35.
101. Dessein P.H., Norton G.R., Badenhorst M., Woodiwiss A.J., Solomon A. Rheumatoid arthritis impacts on the independent relationships between circulating adiponectin concentrations and cardiovascular metabolic risk. Mediators Inflamm 2013, 2013:461849.
102. Gonzalez-Gay M.A., Gonzalez-Juanatey C., Rodriguez-Rodriguez L., Miranda-Filloy J.A., Martin J., Llorca J. Lack of association between adipokines and ghrelin and carotid intima-media thickness in patients with severe rheumatoid arthritis. Clin Exp Rheumatol 2011, 29(2):358-359.
103. Otero M., Lago R., Gomez R., Dieguez C., Lago F., Gomez-Reino J., et al. Towards a pro-inflammatory and immunomodulatory emerging role of leptin. Rheumatology (Oxford) 2006, 45(8):944-950.
104. Rho Y.H., Solus J., Sokka T., Oeser A., Chung C.P., Gebretsadik T., et al. Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. Arthritis Rheum 2009, 60(7):1906-1914.
105. Giles J.T. Adipokine mediators of inflammation and cardiometabolic comorbidity in rheumatoid arthritis: is there a master adipokine?. J Rheumatol 2014, 41(9):1725-1727.
106. Dessein P.H., Tsang L., Woodiwiss A.J., Norton G.R., Solomon A. Circulating concentrations of the novel adipokine chemerin are associated with cardiovascular disease risk in rheumatoid arthritis. J Rheumatol 2014, 41(9):1746-1754.
107. Gonzalez-Gay M.A., Gonzalez-Juanatey C., Pineiro A., Garcia-Porrua C., Testa A., Llorca J. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol 2005, 32(7):1219-1223.
108. Ridker P.M., Bassuk S.S., Toth P.P. C-reactive protein and risk of cardiovascular disease: evidence and clinical application. Curr Atheroscler Rep 2003, 5(5):341-349.
109. Book C., Saxne T., Jacobsson L.T. Prediction of mortality in rheumatoid arthritis based on disease activity markers. J Rheumatol 2005, 32(3):430-434.
110. del Rincon I., Polak J.F., O'Leary D.H., Battafarano D.F., Erikson J.M., Restrepo J.F., et al. Systemic inflammation and cardiovascular risk factors predict rapid progression of atherosclerosis in rheumatoid arthritis. Ann Rheum Dis 2015, 74(6):1118-1123.
111. Eder L., Thavaneswaran A., Chandran V., Cook R., Gladman D.D. Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis. Ann Rheum Dis 2015, 74(10):1830-1835.
112. Ajeganova S., Humphreys J.H., Verheul M.K., van Steenbergen H.W., van Nies J.A., Hafstrom I., et al. Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts. Ann Rheum Dis 2016, [Epub Jan 12].
113. Sokolove J., Brennan M.J., Sharpe O., Lahey L.J., Kao A.H., Krishnan E., et al. Brief report: citrullination within the atherosclerotic plaque: a potential target for the anti-citrullinated protein antibody response in rheumatoid arthritis. Arthritis Rheum 2013, 65(7):1719-1724.
114. Barbarroja N., Perez-Sanchez C., Ruiz-Limon P., Castro-Villegas C., Aguirre M.A., Carretero R., et al. Anticyclic citrullinated protein antibodies are implicated in the development of cardiovascular disease in rheumatoid arthritis. Arterioscler Thromb Vasc Biol 2014, 34(12):2706-2716.
115. Cambridge G., Acharya J., Cooper J.A., Edwards J.C., Humphries S.E. Antibodies to citrullinated peptides and risk of coronary heart disease. Atherosclerosis 2013, 228(1):243-246.
116. Mackey R.H., Kuller L.H., Deane K.D., Walitt B.T., Chang Y.F., Holers V.M., et al. Rheumatoid arthritis, anti-cyclic citrullinated peptide positivity, and cardiovascular disease risk in the Women's Health Initiative. Arthritis Rheumatol 2015, 67(9):2311-2322.
117. Montes A., Corrales A., Calaza M., Lopez-Mejias R., Parra J.A., Gonzalez-Gay M.A., et al. Brief report: lack of replication of an association between anti-citrullinated fibrinogen and subclinical atherosclerosis in patients with rheumatoid arthritis. Arthritis Rheumatol 2015, 67(11):2861-2865.
118. Peters M.J., van Halm V.P., Nurmohamed M.T., Damoiseaux J., Tervaert J.W., Twisk J.W., et al. Relations between autoantibodies against oxidized low-density lipoprotein, inflammation, subclinical atherosclerosis, and cardiovascular disease in rheumatoid arthritis. J Rheumatol 2008, 35(8):1495-1499.
119. Sherer Y., Gerli R., Vaudo G., Schillaci G., Gilburd B., Giordano A., et al. Prevalence of antiphospholipid and antioxidized low-density lipoprotein antibodies in rheumatoid arthritis. Ann N Y Acad Sci 2005, 1051:299-303.
120. Laczik R., Szodoray P., Veres K., Szomjak E., Csipo I., Sipka S., et al. Assessment of IgG antibodies to oxidized LDL in patients with acute coronary syndrome. Lupus 2011, 20(7):730-735.
121. Montecucco F., Steffens S., Mach F. The immune response is involved in atherosclerotic plaque calcification: could the RANKL/RANK/OPG system be a marker of plaque instability?. Clin Dev Immunol 2007, 2007:75805.
122. Asanuma Y., Chung C.P., Oeser A., Solus J.F., Avalos I., Gebretsadik T., et al. Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis. Atherosclerosis 2007, 195(2):e135-e141.
123. Arts E.E., Popa C., Den Broeder A.A., Semb A.G., Toms T., Kitas G.D., et al. Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann Rheum Dis 2015, 74(4):668-674.
124. Solomon D.H., Greenberg J., Curtis J.R., Liu M., Farkouh M.E., Tsao P., et al. Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: a consortium of rheumatology researchers of North America registry study. Arthritis Rheumatol 2015, 67(8):1995-2003.
125. Arts E.E., Popa C.D., Den Broeder A.A., Donders R., Sandoo A., Toms T., et al. Prediction of cardiovascular risk in rheumatoid arthritis: performance of original and adapted SCORE algorithms. Ann Rheum Dis 2015, [Epub Feb 17].
126. Kerekes G., Soltesz P., Nurmohamed M.T., Gonzalez-Gay M.A., Turiel M., Vegh E., et al. Validated methods for assessment of subclinical atherosclerosis in rheumatology. Nat Rev Rheumatol 2012, 8(4):224-234.
127. Gonzalez-Juanatey C., Llorca J., Vazquez-Rodriguez T.R., Diaz-Varela N., Garcia-Quiroga H., Gonzalez-Gay M.A. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum 2008, 59(12):1821-1824.
128. Hansel S., Lassig G., Pistrosch F., Passauer J. Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity. Atherosclerosis 2003, 170(1):177-180.
129. Gerli R., Bartoloni Bocci E., Sherer Y., Vaudo G., Moscatelli S., Shoenfeld Y. Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 2008, 67(5):724-725.
130. Salmon J.E., Roman M.J. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med 2008, 121(10 Suppl. 1):S3-S8.
131. Ambrosino P., Lupoli R., Di Minno A., Tasso M., Peluso R., Di Minno M.N. Subclinical atherosclerosis in patients with rheumatoid arthritis. A meta-analysis of literature studies. Thromb Haemost 2015, 113(5):916-930.
132. Corrales A., Gonzalez-Juanatey C., Peiro M.E., Blanco R., Llorca J., Gonzalez-Gay M.A. Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. Ann Rheum Dis 2014, 73(4):722-727.
133. Corrales A., Parra J.A., Gonzalez-Juanatey C., Rueda-Gotor J., Blanco R., Llorca J., et al. Cardiovascular risk stratification in rheumatic diseases: carotid ultrasound is more sensitive than coronary artery calcification score to detect subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 2013, 72(11):1764-1770.
134. Soltesz P., Der H., Kerekes G., Szodoray P., Szucs G., Danko K., et al. A comparative study of arterial stiffness, flow-mediated vasodilation of the brachial artery, and the thickness of the carotid artery intima-media in patients with systemic autoimmune diseases. Clin Rheumatol 2009, 28(6):655-662.
135. Karpouzas G.A., Malpeso J., Choi T.Y., Li D., Munoz S., Budoff M.J. Prevalence, extent and composition of coronary plaque in patients with rheumatoid arthritis without symptoms or prior diagnosis of coronary artery disease. Ann Rheum Dis 2014, 73(10):1797-1804.
136. Emami H., Vijayakumar J., Subramanian S., Vucic E., Singh P., MacNabb M.H., et al. Arterial 18F-FDG uptake in rheumatoid arthritis correlates with synovial activity. JACC Cardiovasc Imaging 2014, 7(9):959-960.
137. Rose S., Dave J., Millo C., Naik H.B., Siegel E.L., Mehta N.N. Psoriatic arthritis and sacroiliitis are associated with increased vascular inflammation by 18-fluorodeoxyglucose positron emission tomography computed tomography: baseline report from the psoriasis atherosclerosis and cardiometabolic disease Initiative. Arthritis Res Ther 2014, 16(4):R161.
138. Beinsberger J., Heemskerk J.W., Cosemans J.M. Chronic arthritis and cardiovascular disease: altered blood parameters give rise to a prothrombotic propensity. Semin Arthritis Rheum 2014, 44(3):345-352.
139. Ohman M., Ohman M.L., Wallberg-Jonsson S. The apoB/apoA1 ratio predicts future cardiovascular events in patients with rheumatoid arthritis. Scand J Rheumatol 2014, 43(4):259-264.
140. Navarro-Millan I., Yang S., DuVall S.L., Chen L., Baddley J., Cannon G.W., et al. Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration. Ann Rheum Dis 2016, 75(2):341-347.
141. Mirjafari H., Welsh P., Verstappen S.M., Wilson P., Marshall T., Edlin H., et al. N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and mortality risk in early inflammatory polyarthritis: results from the Norfolk arthritis registry (NOAR). Ann Rheum Dis 2014, 73(4):684-690.
142. Avouac J., Meune C., Chenevier-Gobeaux C., Dieude P., Borderie D., Lefevre G., et al. Inflammation and disease activity are associated with high circulating cardiac markers in rheumatoid arthritis independently of traditional cardiovascular risk factors. J Rheumatol 2014, 41(2):248-255.
143. McInnes I.B., Thompson L., Giles J.T., Bathon J.M., Salmon J.E., Beaulieu A.D., et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis 2015, 74(4):694-702.
144. Costenbader K.H., Coblyn J.S. Statin therapy in rheumatoid arthritis. South Med J 2005, 98(5):534-540.
145. Timar O., Szekanecz Z., Kerekes G., Vegh J., Olah A.V., Nagy G., et al. Rosuvastatin improves impaired endothelial function, lowers high sensitivity CRP, complement and immuncomplex production in patients with systemic sclerosis-a prospective case-series study. Arthritis Res Ther 2013, 15(5):R105.
146. McCarey D.W., McInnes I.B., Madhok R., Hampson R., Scherbakov O., Ford I., et al. Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004, 363(9426):2015-2021.
147. Ormseth M.J., Oeser A.M., Cunningham A., Bian A., Shintani A., Solus J., et al. Reversing vascular dysfunction in rheumatoid arthritis: improved augmentation index but not endothelial function with peroxisome proliferator-activated receptor gamma agonist therapy. Arthritis Rheumatol 2014, 66(9):2331-2338.
148. Essouma M., Noubiap J.J. Therapeutic potential of folic acid supplementation for cardiovascular disease prevention through homocysteine lowering and blockade in rheumatoid arthritis patients. Biomark Res 2015, 3:24.
149. Suissa S., Bernatsky S., Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum 2006, 55(4):531-536.
150. Scott P.A., Kingsley G.H., Smith C.M., Choy E.H., Scott D.L. Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis 2007, 66(10):1296-1304.
151. Roubille C., Richer V., Starnino T., McCourt C., McFarlane A., Fleming P., et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015, 74(3):480-489.
152. Tsai W.C., Ou T.T., Yen J.H., Wu C.C., Tung Y.C. Long-term frequent use of non-steroidal anti-inflammatory drugs might protect patients with ankylosing spondylitis from cardiovascular diseases: a nationwide case-control study. PLoS One 2015, 10(5).
153. Ferraz-Amaro I., Machin S., Carmona L., Gonzalez-Alvaro I., Diaz-Gonzalez F., Group Es Pattern of use and safety of non-steroidal anti-inflammatory drugs in rheumatoid arthritis patients. A prospective analysis from clinical practice. Reumatol Clin 2009, 5(6):252-258.
154. Nurmohamed M.T., van Halm V.P., Dijkmans B.A. Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis. Drugs 2002, 62(11):1599-1609.
155. Black R.J., Joseph R.M., Brown B., Movahedi M., Lunt M., Dixon W.G. Half of UK patients with rheumatoid arthritis are prescribed oral glucocorticoid therapy in primary care: a retrospective drug utilisation study. Arthritis Res Ther 2015, 17(1):375.
156. Konijn N., van Tuyl L., Den Uijl D., Ter Wee M., Kerstens P., Voskuyl A., et al. Prednisolone causes dose related unfavourable effects on body composition in early rheumatoid arthritis patients during the first year of treatment. Ann Rheum Dis 2015, 74(Suppl. 2):239.
157. Maradit-Kremers H., Nicola P.J., Crowson C.S., Ballman K.V., Gabriel S.E. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005, 52(3):722-732.
158. Ajeganova S., Svensson B., Hafstrom I., Group B.S. Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial. BMJ Open 2014, 4(4).
159. van Sijl A.M., Boers M., Voskuyl A.E., Nurmohamed M.T. Confounding by indication probably distorts the relationship between steroid use and cardiovascular disease in rheumatoid arthritis: results from a prospective cohort study. PLoS One 2014, 9(1).
160. Toms T.E., Panoulas V.F., Douglas K.M., Griffiths H.R., Kitas G.D. Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther 2008, 10(6):R145.
161. Boers M. Drugs and cardiovascular risk in inflammatory arthritis: another case of glucocorticoid-bashing?. Ann Rheum Dis 2015, 74(5).
162. del Rincon I., Battafarano D.F., Restrepo J.F., Erikson J.M., Escalante A. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol 2014, 66(2):264-272.
163. Micha R., Imamura F., Wyler von Ballmoos M., Solomon D.H., Hernan M.A., Ridker P.M., et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011, 108(9):1362-1370.
164. Ronda N., Greco D., Adorni M.P., Zimetti F., Favari E., Hjeltnes G., et al. Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism. Arthritis Rheumatol 2015, 67(5):1155-1164.
165. De Vecchis R., Baldi C., Palmisani L. Protective effects of methotrexate against ischemic cardiovascular disorders in patients treated for rheumatoid arthritis or psoriasis: novel therapeutic insights coming from a meta-analysis of the literature data. Anatol J Cardiol 2016, 16:2-9.
166. Ridker P.M., Luscher T.F. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J 2014, 35(27):1782-1791.
167. Kerr G., Aujero M., Richards J., Sayles H., Davis L., Cannon G., et al. Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications. Arthritis Care Res (Hoboken) 2014, 66(11):1619-1626.
168. Hage M.P., Al-Badri M.R., Azar S.T. A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role. Ther Adv Endocrinol Metab 2014, 5(4):77-85.
169. van Halm V.P., Nurmohamed M.T., Twisk J.W., Dijkmans B.A., Voskuyl A.E. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006, 8(5):R151.
170. Minoretti P., Bruno A., Di Vito C., Emanuele E. Leflunomide as an antiatherogenic drug. Med Hypotheses 2007, 68(5):1175-1176.
171. Szekanecz Z., Kerekes G., Soltesz P. Vascular effects of biologic agents in RA and spondyloarthropathies. Nat Rev Rheumatol 2009, 5(12):677-684.
172. Choy E., Ganeshalingam K., Semb A.G., Szekanecz Z., Nurmohamed M. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford) 2014, [Epub Jun 8].
173. Greenberg J.D., Furer V., Farkouh M.E. Cardiovascular safety of biologic therapies for the treatment of RA. Nat Rev Rheumatol 2012, 8(1):13-21.
174. Gonzalez-Juanatey C., Testa A., Garcia-Castelo A., Garcia-Porrua C., Llorca J., Gonzalez-Gay M.A. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum 2004, 51(3):447-450.
175. Sidiropoulos P.I., Siakka P., Pagonidis K., Raptopoulou A., Kritikos H., Tsetis D., et al. Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients. Scand J Rheumatol 2009, 38(1):6-10.
176. Capria A., De Nardo D., Baffetti F.R., Barbini U., Violo A., Tondo T., Fontana L. Long-term anti-TNF-alpha treatments reverse the endothelial dysfunction in rheumatoid arthritis: the biological coherence between synovial and endothelial inflammation. Int J Immunopathol Pharmacol 2010, 23(1):255-262.
177. Kerekes G., Soltesz P., Szucs G., Szamosi S., Der H., Szabo Z., et al. Effects of adalimumab treatment on vascular disease associated with early rheumatoid arthritis. Isr Med Assoc J 2011, 13(3):147-152.
178. Del Porto F., Lagana B., Lai S., Nofroni I., Tinti F., Vitale M., et al. Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology (Oxford) 2007, 46(7):1111-1115.
179. Maki-Petaja K.M., Hall F.C., Booth A.D., Wallace S.M., Yasmin, Bearcroft P.W., et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 2006, 114(11):1185-1192.
180. Kume K., Amano K., Yamada S., Hatta K., Ohta H., Kuwaba N. Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial. J Rheumatol 2011, 38(10):2169-2171.
181. Van Doornum S., McColl G., Wicks I.P. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. Rheumatology (Oxford) 2005, 44(11):1428-1432.
182. Robertson J., Peters M.J., McInnes I.B., Sattar N. Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol 2013.
183. Chen D.Y., Chen Y.M., Hsieh T.Y., Hsieh C.W., Lin C.C., Lan J.L. Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis. Arthritis Res Ther 2015, 17:52.
184. Garces S.P., Parreira Santos M.J., Vinagre F.M., Roque R.M., da Silva J.A. Anti-tumour necrosis factor agents and lipid profile: a class effect?. Ann Rheum Dis 2008, 67(6):895-896.
185. Abella V., Scotece M., Conde J., Lopez V., Lazzaro V., Pino J., et al. Adipokines, metabolic syndrome and rheumatic diseases. J Immunol Res 2014, 2014:343746.
186. Myasoedova E., Crowson C.S., Nicola P.J., Maradit-Kremers H., Davis J.M., Roger V.L., et al. The influence of rheumatoid arthritis disease characteristics on heart failure. J Rheumatol 2011, 38(8):1601-1606.
187. Burska A.N., Sakthiswary R., Sattar N. Effects of tumour necrosis factor antagonists on insulin sensitivity/resistance in rheumatoid arthritis: A systematic review and Meta-Analysis. PLoS One 2015, 10(6).
188. Metsios G.S., Stavropoulos-Kalinoglou A., Douglas K.M., Koutedakis Y., Nevill A.M., Panoulas V.F., et al. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia. Rheumatology (Oxford) 2007, 46(12):1824-1827.
189. Challal S., Minichiello E., Boissier M.C., Semerano L. Cachexia and adiposity in rheumatoid arthritis. Relevance for disease management and clinical outcomes. Joint Bone Spine 2015, [Epub Jul 13].
190. Marcora S.M., Chester K.R., Mittal G., Lemmey A.B., Maddison P.J. Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr 2006, 84(6):1463-1472.
191. Manfredi A.A., Baldini M., Camera M., Baldissera E., Brambilla M., Peretti G., et al. Anti-TNFalpha agents curb platelet activation in patients with rheumatoid arthritis. Ann Rheum Dis 2016, [Epub Jan 27].
192. Westlake S.L., Colebatch A.N., Baird J., Curzen N., Kiely P., Quinn M., et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2011, 50(3):518-531.
193. Jacobsson L.T., Turesson C., Gulfe A., Kapetanovic M.C., Petersson I.F., Saxne T., et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005, 32(7):1213-1218.
194. Morgan C.L., Emery P., Porter D., Reynolds A., Young A., Boyd H., et al. Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data. Rheumatology (Oxford) 2014, 53(1):186-194.
195. Greenberg J.D., Furer V., Farkouh M.E. Cardiovascular safety of biologic therapies for the treatment of RA. Nat Rev Rheumatol 2011, 8(1):13-21.
196. Nurmohamed M., Bao Y., Signorovitch J., Trahey A., Mulani P., Furst D.E. Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis. RMD Open 2015, 1(1).
197. Bili A., Tang X., Pranesh S., Bozaite R., Morris S.J., Antohe J.L., et al. Tumor necrosis factor alpha inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014, 66(3):355-363.
198. Ljung L., Askling J., Rantapaa-Dahlqvist S., Jacobsson L., Group A.S. The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study. Arthritis Res Ther 2014, 16(3):R127.
199. Kirkham B.W., Wasko M.C., Hsia E.C., Fleischmann R.M., Genovese M.C., Matteson E.L., et al. Effects of golimumab, an anti-tumour necrosis factor-alpha human monoclonal antibody, on lipids and markers of inflammation. Ann Rheum Dis 2014, 73(1):161-169.
200. Wasko M.C., Hsia E.C., Kirkham B., Touboul P.J., Fleischmann R., Genovese M.C., et al. Effect of golimumab on carotid atherosclerotic disease measures and cardiovascular events in inflammatory arthritides. J Clin Rheumatol 2014, 20(1):1-10.
201. Heathfield S.K., Parker B., Zeef L.A., Bruce I.N., Alexander M.Y. Certolizumab pegol attenuates the pro-inflammatory state in endothelial cells in a manner that is atheroprotective. Clin Exp Rheumatol 2013, 31(2):225-233.
202. Kerekes G., Soltesz P., Der H., Veres K., Szabo Z., Vegvari A., et al. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol 2009, 28(6):705-710.
203. Hsue P.Y., Scherzer R., Grunfeld C., Imboden J., Wu Y., Del Puerto G., et al. Depletion of B-cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis. J Am Heart Assoc 2014, 3(5).
204. Harrold L.R., Reed G.W., Magner R., Shewade A., John A., Greenberg J.D., et al. Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States corrona registry. Arthritis Res Ther 2015, 17:256.
205. Curtis J.R., Perez-Gutthann S., Suissa S., Napalkov P., Singh N., Thompson L., et al. Tocilizumab in rheumatoid arthritis: a case study of safety evaluations of a large postmarketing data set from multiple data sources. Semin Arthritis Rheum 2015, 44(4):381-388.
206. Souto A., Salgado E., Maneiro J.R., Mera A., Carmona L., Gomez-Reino J.J. Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis Rheumatol 2015, 67(1):117-127.
207. Gabay C., McInnes I.B., Kavanaugh A., Tuckwell K., Klearman M., Pulley J., et al. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis 2015, [Epub Nov 27].
208. Protogerou A.D., Zampeli E., Fragiadaki K., Stamatelopoulos K., Papamichael C., Sfikakis P.P. A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis. Atherosclerosis 2011, 219(2):734-736.
209. Zhang J., Xie F., Yun H., Chen L., Muntner P., Levitan E.B., et al. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis 2016, [Epub Jan 20].
210. Ursini F., Russo E., Letizia Hribal M., Mauro D., Savarino F., Bruno C., et al. Abatacept improves whole-body insulin sensitivity in rheumatoid arthritis: an observational study. Medicine (Baltimore) 2015, 94(21).
211. Ikonomidis I., Tzortzis S., Andreadou I., Paraskevaidis I., Katseli C., Katsimbri P., et al. Increased benefit of interleukin-1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis. Circ Cardiovasc Imaging 2014, 7(4):619-628.
212. Charles-Schoeman C., Fleischmann R., Davignon J., Schwartz H., Turner S.M., Beysen C., et al. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol 2015, 67(3):616-625.
213. van Vollenhoven R.F., Fleischmann R., Cohen S., Lee E.B., Garcia Meijide J.A., Wagner S., et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012, 367(6):508-519.
214. Metsios G.S., Stavropoulos-Kalinoglou A., Veldhuijzen van Zanten J.J., Treharne G.J., Panoulas V.F., Douglas K.M., et al. Rheumatoid arthritis, cardiovascular disease and physical exercise: a systematic review. Rheumatology (Oxford) 2008, 47(3):239-248.
215. Metsios G.S., Stavropoulos-Kalinoglou A., Veldhuijzen van Zanten J.J., Nightingale P., Sandoo A., Dimitroulas T., et al. Individualised exercise improves endothelial function in patients with rheumatoid arthritis. Ann Rheum Dis 2014, 73(4):748-751.
216. Stavropoulos-Kalinoglou A., Metsios G.S., Veldhuijzen van Zanten J.J., Nightingale P., Kitas G.D., Koutedakis Y. Individualised aerobic and resistance exercise training improves cardiorespiratory fitness and reduces cardiovascular risk in patients with rheumatoid arthritis. Ann Rheum Dis 2013, 72(11):1819-1825.
217. Sveaas S.H., Berg I.J., Provan S.A., Semb A.G., Hagen K.B., Vollestad N., et al. Efficacy of high intensity exercise on disease activity and cardiovascular risk in active axial spondyloarthritis: a randomized controlled pilot study. PLoS One 2014, 9(9).
218. Hollan I., Dessein P.H., Ronda N., Wasko M.C., Svenungsson E., Agewall S., et al. Prevention of cardiovascular disease in rheumatoid arthritis. Autoimmun Rev 2015, 14(10):952-969.